Crizotinib manufacturers and latest price information

Crizotinib (Crizotinib) was originally developed and marketed by Pfizer under the trade name XALKORI. Currently, in the market, in addition to the imported version of Pfizer, there are also many pharmaceutical companies producing generic versions of crizotinib, which provides patients with more treatment options. This article will give you a detailed introduction to the latest information on the price of crizotinib at home and abroad.

In my country, as a high-end anti-tumor drug, the price of crizotinib has always attracted much attention. At present, a box of crizotinib capsules with a specification of 250mg*60 capsules is generally sold at a high price in major pharmacies, and the price may reach thousands or even tens of thousands of yuan. However, crizotinib has been included in the medical insurance reimbursement catalog, and eligible patients can enjoy certain reimbursement discounts. However, specific reimbursement policies vary by region, and patients are advised to consult their local medical insurance bureau to obtain the most accurate information.

For some patients who are not eligible for reimbursement or who still have great financial pressure after reimbursement, generic versions of crizotinib are also available overseas. Especially in some Southeast Asian countries, there are multiple versions of crizotinib generics, and the price is relatively affordable. For example, the Lucius version of crizotinib in Laos is priced at more than 1,000 yuan per box (250mg*60 pills); while the Bangladeshi Ziska version of the drug of the same specification is sold at around 2,000 yuan. The emergence of these overseas generic drugs provides more treatment options for patients with limited financial conditions. It should be noted that although overseas generic drugs are cheaper, domestic patients need to be cautious when purchasing them. Patients should ensure that the source of medicines is regular and reliable, and avoid buying fake and shoddy products.

In summary, crizotinib, as an important anti-tumor drug, is sold in both domestic and foreign markets. When patients choose to purchase, they should comprehensively consider their own financial conditions, disease status, medical insurance reimbursement policies and other factors to make the decision that is most suitable for them.